NCT05931757 is a Phase 2 clinical trial of Olverembatinib in Philadelphia-Positive ALL, sponsored by The First Affiliated Hospital of Soochow University.

Who is sponsoring NCT05931757?

NCT05931757 is sponsored by The First Affiliated Hospital of Soochow University.

What drugs are being tested in NCT05931757?

Interventions in NCT05931757: Olverembatinib.

What condition does NCT05931757 study?

NCT05931757 studies Philadelphia-Positive ALL.

Is NCT05931757 still recruiting?

NCT05931757 is currently not yet recruiting. Last updated 5 July 2023.

Last reviewed 2023-07-05 · How we verify

NCT05931757

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL

Not yet recruiting Phase 2 Last updated 5 July 2023

What this trial tests

Phase 2 trial testing Olverembatinib in Philadelphia-Positive ALL in 22 participants. Not yet recruiting.

Timeline

1 July 2023

Primary endpoint
30 June 2025

30 June 2030

Quick facts

Lead sponsor	The First Affiliated Hospital of Soochow University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	1 July 2023
Primary completion	30 June 2025
Estimated completion	30 June 2030
Sites	1 location across China

Drugs / interventions tested

Olverembatinib — full drug profile →

Conditions studied

Philadelphia-Positive ALL — all drugs for Philadelphia-Positive ALL →

Sponsor

The First Affiliated Hospital of Soochow University

Who can join

Adults 18 to 100, any sex, with Philadelphia-Positive ALL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, prospective, phase II study for adult de novo Philadelphia chromosome-positive acute lymphoid leukemia (Ph+ ALL) based on the combination of Olverembatinib and Blinatumomab. Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy.
Halder P, Rai A, Talukdar V, Das P, et al · · 2024 · cited 7× · PMID 38784451 · DOI 10.1039/d4md00003j
Efficacy and safety of blinatumomab combination therapy in high-risk B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis.
Wang M, Yu X, Zou Z, He Y, et al · · 2026 · PMID 41947896 · DOI 10.3892/ol.2026.15552
Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies-a comprehensive review of clinical outcomes.
Sadati S, Yazdizadeh S, Razavi SM, Homayoonfal M, et al · · 2026 · PMID 41547674 · DOI 10.1007/s12672-026-04438-x

Verify or expand the search:

Other trials of Olverembatinib

Trials testing the same drug.

NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07493161 — Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL · NA · not yet recruiting
NCT06757855 — Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML · Phase 1, PHASE2 · recruiting
NCT06640361 — A Study of Olverembatinib in SDH-deficient GIST. · Phase 3 · recruiting
NCT06401603 — A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Ph · Phase 1 · recruiting

Other recruiting trials for Philadelphia-Positive ALL

Currently open trials in the same condition.

NCT06287528 — A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) · Phase 1 · recruiting
NCT06220487 — A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With New · Phase 2 · recruiting

Other The First Affiliated Hospital of Soochow University trials

Trials by the same sponsor.

NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05931757 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
Last refreshed: 5 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05931757.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing